Jančić, Ivan <br/><br/>
174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis.  [electronic resource] 

 -  Rheumatology international  Jun 2013 
 - 1481-6 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1437-160X 
<br/><br/><label>Standard No.: </label>10.1007/s00296-012-2586-y  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antirheumatic Agents--therapeutic use<br/>Arthritis, Rheumatoid--drug therapy<br/>Etanercept<br/>Female<br/>Genotype<br/>Humans<br/>Immunoglobulin G--therapeutic use<br/>Interleukin-6--genetics<br/>Male<br/>Middle Aged<br/>Polymorphism, Genetic<br/>Promoter Regions, Genetic<br/>Receptors, Tumor Necrosis Factor--therapeutic use<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors